1. Home
  2. MATV vs FULC Comparison

MATV vs FULC Comparison

Compare MATV & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mativ Holdings Inc.

MATV

Mativ Holdings Inc.

HOLD

Current Price

$9.21

Market Cap

494.1M

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$8.21

Market Cap

535.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATV
FULC
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
494.1M
535.5M
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
MATV
FULC
Price
$9.21
$8.21
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
483.5K
985.3K
Earning Date
05-06-2026
04-30-2026
Dividend Yield
4.32%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.97
N/A
Revenue Next Year
$4.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.45
$3.05
52 Week High
$15.48
$15.74

Technical Indicators

Market Signals
Indicator
MATV
FULC
Relative Strength Index (RSI) 51.13 55.14
Support Level $8.02 $6.35
Resistance Level $13.03 $8.20
Average True Range (ATR) 0.32 0.49
MACD 0.22 0.17
Stochastic Oscillator 86.51 92.90

Price Performance

Historical Comparison
MATV
FULC

About MATV Mativ Holdings Inc.

Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: